The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
See JNCCN.org for supplemental online content.
Schiffmann J, Gandaglia G, Larcher A et al.. Contemporary 90-day mortality rates after radical cystectomy in the elderly. Eur J Surg Oncol 2014;40:1738–1745.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
Miller DC, Taub DA, Dunn RL et al.. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol 2003;169:105–109.
Alfred Witjes J, Lebret T, Comperat EM et al.. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017;71:462–475.
Warren JL, Klabunde CN, Schrag D et al.. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8 Suppl):IV-3–18.
Burnham KP, Anderson DR. Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach. New York, NY: Springer Science & Business Media; 2002.
Burnham KP, Anderson DR. Multimodel inference understanding AIC and BIC in model selection. Sociol Methods Res 2004;33:261–304.
Hammill BG, Curtis LH, Bennett-Guerrero E et al.. Impact of heart failure on patients undergoing major noncardiac surgery. Anesthesiology 2008;108:559–567.
Higgins TL, Estafanous FG, Loop FD et al.. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. JAMA 1992;267:2344–2348.
Jorgensen ME, Torp-Pedersen C, Gislason GH et al.. Time elapsed after ischemic stroke and risk of adverse cardiovascular events and mortality following elective noncardiac surgery. JAMA 2014;312:269–277.
Licker MJ, Widikker I, Robert J et al.. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. Ann Thorac Surg 2006;81:1830–1837.
Virani S, Michaelson JS, Hutter MM et al.. Morbidity and mortality after liver resection: results of the patient safety in surgery study. J Am Coll Surg 2007;204:1284–1292.
Krolikowska M, Kataja M, Poyhia R et al.. Mortality in diabetic patients undergoing non-cardiac surgery: a 7-year follow-up study. Acta Aanaesthesiol Scand 2009;53:749–758.
Emerging Risk Factors Collaboration Seshasai SR, Kaptoge S et al.. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829–841.
Thourani VH, Weintraub WS, Stein B et al.. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999;67:1045–1052.
Oh JJ, Kang MY, Jo JK et al.. Association between diabetes mellitus and oncological outcomes in bladder cancer patients undergoing radical cystectomy. Int J Urol 2015;22:1112–1117.
Patel HD, Kates M, Pierorazio PM et al.. Comorbidities and causes of death in the management of localized T1a kidney cancer. Int J Urol 2014;21:1086–1092.
Hemmelgarn BR, Manns BJ, Quan H, Ghali WA. Adapting the Charlson comorbidity index for use in patients with ESRD. Am J Kidney Dis 2003;42:125–132.
Klabunde CN, Legler JM, Warren JL et al.. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17:584–590.
Fleming ST, Rastogi A, Dmitrienko A, Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care 1999;37:601–614.
Fleming ST, Pearce KA, McDavid K, Pavlov D. The development and validation of a comorbidity index for prostate cancer among black men. J Clin Epidemiol 2003;56:1064–1075.
Colinet B, Jacot W, Bertrand D et al.. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 2005;93:1098–1105.
Sorror ML, Maris MB, Storb R et al.. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–2919.
Sachdev M, Sun JL, Tsiatis AA et al.. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol 2004;43:576–582.
Liu J, Huang Z, Gilbertson DT et al.. An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 2010;77:141–151.
Piccirillo JF, Tierney RM, Costas I et al.. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291:2441–2447.
Oken MM, Creech RH, Tormey DC et al.. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
Mayr R, May M, Martini T et al.. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder. BJU Int 2012;110:E222–227.
Psutka SP, Carrasco A, Schmit GD et al.. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 2014;120:2910–2918.
Chappidi MR, Kates M, Patel HD et al.. Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. Urol Oncol 2016;34:256 e1–6.